Olga Andreeva
Head of Expanded Access Center of Excellence Novo Nordisk
Olga Andreeva leads global Expanded Access, Early Access, and Compassionate Use programmes at Novo Nordisk, focusing on designing and implementing strategies that enable responsible and sustainable patient access to investigational therapies. With over 15 years of experience across life sciences and non-profit sectors, she specialises in post-trial access, global programme governance, and bridging clinical development with commercialization. Olga brings deep expertise in navigating complex, multi-country environments and is passionate about ensuring continuity of care while balancing regulatory, operational, and long-term portfolio considerations.
Seminars
This fast-paced session delivers practical, on-the-ground solutions to common EAP challenges. Featuring a series of concise, ten-minute spotlights from leading biopharma, each presentation highlights a single innovation or tactic that helped unlock access, streamline processes, or support patient continuity. Designed to fuel actionable discussion, this session goes beyond the theory – focusing on what’s actually working, and where we go next.
This session brings together two real-world case studies to explore how organisations have managed the transition from clinical trial systems into post-trial access.
- Managing the transition from trial supply to post trial access without disrupting patient treatment
- Resetting site expectations around ordering, reporting, and documentation outside trial frameworks
- Addressing practical blockers in complex regions where PTA setup is slower, less defined, or inconsistently interpreted
- Deciding when post trial access can accommodate limited data collection and when patients must remain in extension studies instead
